Company: ARTL
Filing Date: 2025-09-30
Form Type: 424B5
Source: 0001640334-25-001749
Chunk: 22

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: 424B5
Chunk 22
---
otment option in full), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering to advance our product candidates through preclinical and clinical development, including manufacturing, research and technical development, clinical studies, capital expenditures, and for working capital and general corporate purposes. In addition, we may use the net proceeds from this offering for investments in products or technologies that are complementary to our business, although we have no present commitments or agreements to make any such investments as of the date of this prospectus.

This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. As a result, we cannot specify with certainty all of the particular uses of the proceeds from this offering. Accordingly, our management will retain broad discretion over the allocation of the net proceeds from this offering.

Pending use of the proceeds as described above or otherwise, we intend to invest the net proceeds of this offering in government securities, high quality short-term corporate debt obligations and SEC-registered money market accounts.

| S-9 |

<div align='center'>CAPITALIZATION</div>

The table below sets forth our capitalization and indebtedness as of June 30, 2025:

| ● | on an actual basis; and |

| ● | on an as adjusted basis to give further effect to this offering based on a public offering price of $[ ] per share of common stock and a public offering price of $[ ] per Pre-funded Warrant, after deducting the underwriting discounts, and estimated offering expenses payable by us. |

You should read this table together with our consolidated financial statements and notes included in the information incorporated by reference into this prospectus supplement and the accompanying prospectus.

|                                                                                                                             |     | As of June 30, 2025  |         |   |     |                         |   |
|:----------------------------------------------------------------------------------------------------------------------------|:----|:---------------------|--------:|:--|:----|:------------------------|:--|
|                                                                                                                             |     | Actual  (Unaudited)  |         |   |     | As Adjusted (Unaudited) |   |
|                                                                                                                             |     | -U.S. $ in thousands |         |   |     |                         |   |
| Cash and cash equivalents                                                                                                   |     | $                    |   2,066 |   |     | $                       | - |
| Total